Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14676725 | 0.85 | ALPL (0.53) | ALPLHTTALDH1A1LMNAPOLB | |
| SCHEMBL16305322 | 0.85 | ALPL (0.60) | ALPLHTTALDH1A1LMNAPOLB | |
| SCHEMBL17526121 | 0.81 | ALDH1A1 (0.59) | HTTALDH1A1LMNAPOLBL3MBTL1 | |
| SCHEMBL1098646 | 0.80 | HTT (0.60) | ALPLHTTALDH1A1LMNAPOLB | |
| SCHEMBL2032272 | 0.79 | HTT (0.63) | ALPLHTTALDH1A1LMNAPOLB | |
| SCHEMBL38656746 | 0.79 | HTT (0.63) | ALPLHTTALDH1A1LMNAPOLB | |
| SCHEMBL282513 | 0.79 | HTT (0.58) | ALPLHTTALDH1A1LMNAPOLB | |
| SCHEMBL17373258 | 0.79 | HTT (0.58) | ALPLHTTALDH1A1LMNAPOLB | |
| SCHEMBL2243891 | 0.79 | ALPL (0.66) | ALPLHTTALDH1A1LMNAPOLB | |
| SCHEMBL2237430 | 0.79 | ALPL (0.66) | ALPLHTTALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312225-B2 | Macrocyclic pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2007-12-25 | — | — | US | disclosed |
| US-7312225-B2 | Macrocyclic pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2007-12-25 | — | — | US | disclosed |
| US-7312225-B2 | Macrocyclic pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2007-12-25 | — | — | US | disclosed |
| EP-1530574-B1 | MACROCYCLIC PYRIMIDINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS | SCHERING AG (DE) | 2006-11-22 | — | — | EP | disclosed |
| US-20040209895-A1 | inhibit cyclin-dependent kinases and VEGF-receptor tyrosine kinases | SCHERING AG (DE) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209895-A1 | inhibit cyclin-dependent kinases and VEGF-receptor tyrosine kinases | CCNK, CDK2, CDK1 | ALPL 4580/4885HTT 4545/4885ALDH1A1 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.